# Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas

> **NCT02547350** · PHASE2 · UNKNOWN · sponsor: **Xuesong Li** · enrollment: 200 (estimated)

## Conditions studied

- Upper Tract Urothelial Carcinoma
- Bladder Recurrence

## Interventions

- **DRUG:** pharmorubicin or pirarubicin

## Key facts

- **NCT ID:** NCT02547350
- **Lead sponsor:** Xuesong Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-09
- **Primary completion:** 2020-12
- **Final completion:** —
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2015-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02547350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02547350, "Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02547350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*